InsiderTrades

Form 4 for ACRS Aclaris Therapeutics, Inc.

Accepted 2026-03-03 00:00:00 ET · period of report 2026-03-01 · accession 0001957554-26-000011 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
D 2026-03-03 2026-03-01 ACRS Balthaser Kevin CFO F - Tax $2.87 -677 187.5K -0.4% -$1,943
D 2026-03-03 2026-03-01 ACRS Balthaser Kevin CFO M - OptEx — +2,375 188.1K +1% —
D 2026-03-03 2026-03-01 ACRS Balthaser Kevin CFO M - OptEx $0.00 -2,375 0 -100% $0

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2026-03-01 F D 677 $2.87 187,453 D — —
2 Common Common Stock 2026-03-01 M A 2,375 — 188,130 D — — (F1) Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer.
3 Derivative Restricted Stock Units 2026-03-01 M D 2,375 $0.00 0 D — · — to — 2,375 Common Stock (F1) Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. (F3) The shares underlying these restricted stock units vest in four equal annual installments beginning on March 1, 2023, subject to the Continuous Service of the Reporting Person (as defined in the Plan) as of the applicable vesting date.